This trial discontinued on 2 May 2008 due to lack of enrolment

The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.

Inclusion Criteria:

• Diagnosis of Schizophrenia
• 18-65 years
• No hospitalization for an exacerbation of schizophrenia within two months prior to screening and during the screening period

Exclusion Criteria:

• Subjects who are acutely psychotic or subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
• At significant risk of suicide, and the potential for violent behavior (likely to harm themselves or others) based on history